RxDoctor Payments Data

Leah Lester

Family · Chattanooga, TNNPI 1154095321

Payments from drug & device makers

$2,682in general payments, 2019–2025

Across 143 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$596
  • Lilly USA, LLC$319
  • Novo Nordisk$259
  • Pfizer$188
  • Takeda Pharmaceuticals U.S.A., Inc.$179
  • Medtronic$167
  • plus $973 from 21 others

What the payments were for

  • Food & beverage$2,682100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,682 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$32,370
Medicare patients
182
Services billed
636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$45,579
TrulicityDulaglutide27$32,951
EliquisApixaban43$32,506
MounjaroTirzepatide21$28,045
JardianceEmpagliflozin30$24,026
VraylarCariprazine Hcl15$21,632
FarxigaDapagliflozin Propanediol25$18,799
JanuviaSitagliptin Phosphate18$16,485
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$16,280
RybelsusSemaglutide12$15,746
Repatha SureclickEvolocumab18$10,038
EntrestoSacubitril/Valsartan13$8,411
Dexlansoprazole DrDexlansoprazole13$7,115
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$5,952
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$4,442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$259$61,32659 claims
Lilly USA, LLCTrulicity, Mounjaro$319$60,99648 claims
PfizerEliquis$188$32,50643 claims
Boehringer IngelheimJardiance$15$24,02630 claims
AbbVieVraylar$596$21,63215 claims
AstraZenecaFarxiga$82$18,79925 claims
GSKTrelegy Ellipta$26$16,28021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →